Literature DB >> 17914084

Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations.

Karin Jordan1, Christoph Sippel, Hans-Joachim Schmoll.   

Abstract

Clinicians should be aware that chemotherapy-induced nausea and vomiting (CINV) is still one of the most feared side effects of chemotherapy. With the correct use of antiemetics, CINV can be prevented in almost 70% to up to 80% of patients. Treatment guidelines are useful tools that enable physicians to integrate the latest clinical research into their practices. The large volume of rapidly evolving clinical data has been summarized and incorporated into treatment recommendations by well-known and reliable institutions, including the Multinational Association of Supportive Care in Cancer, the American Society of Clinical Oncology, and the National Comprehensive Cancer Network. Despite the availability of such guidelines, however, there is evidence that adherence to and implementation of treatment recommendations are less than optimal. This review focuses, in particular, on the conformity and differences of these three guidelines. Furthermore, open questions and trends in the field of antiemesis are discussed as well.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17914084     DOI: 10.1634/theoncologist.12-9-1143

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  53 in total

1.  Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a U.S. population.

Authors:  Amin Haiderali; Laura Menditto; Margaret Good; April Teitelbaum; Jessica Wegner
Journal:  Support Care Cancer       Date:  2010-06-09       Impact factor: 3.603

2.  Guidelines for the control of nausea and vomiting with chemotherapy of low or minimal emetic potential.

Authors:  Ian Olver; Rebecca A Clark-Snow; Enzo Ballatori; Birgitte T Espersen; Emilio Bria; Karin Jordan
Journal:  Support Care Cancer       Date:  2010-08-29       Impact factor: 3.603

Review 3.  The Two Faces of Adjuvant Glucocorticoid Treatment in Ovarian Cancer.

Authors:  Vladimir Djedovic; Yoo-Young Lee; Alexandra Kollara; Taymaa May; Theodore J Brown
Journal:  Horm Cancer       Date:  2018-01-08       Impact factor: 3.869

4.  Aprepitant for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy.

Authors:  Takako Inoue; Madoka Kimura; Junji Uchida; Kazumi Nishino; Toru Kumagai; Junko Taniguchi; Fumio Imamura
Journal:  Int J Clin Oncol       Date:  2017-01-31       Impact factor: 3.402

5.  Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study.

Authors:  Bernardo L Rapoport; Karin Jordan; Judith A Boice; Arlene Taylor; Carole Brown; James S Hardwick; Alexandra Carides; Timothy Webb; Hans-Joachim Schmoll
Journal:  Support Care Cancer       Date:  2009-07-01       Impact factor: 3.603

Review 6.  Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients.

Authors:  Michelle C Janelsins; Mohamedtaki A Tejani; Charles Kamen; Anita R Peoples; Karen M Mustian; Gary R Morrow
Journal:  Expert Opin Pharmacother       Date:  2013-04       Impact factor: 3.889

Review 7.  Supportive care for patients with early breast cancer.

Authors:  Laura García-Estévez; Ignasi Tusquets; Isabel Alvarez; César Rodríguez; Yolanda Fernández; Miguel Angel Seguí; Jesús García-Mata; Ana Lluch
Journal:  Clin Transl Oncol       Date:  2010-01       Impact factor: 3.405

8.  Adverse drug reaction profile of cisplatin-based chemotherapy regimen in a tertiary care hospital in India: An evaluative study.

Authors:  A Surendiran; N Balamurugan; K Gunaseelan; Shahid Akhtar; K S Reddy; C Adithan
Journal:  Indian J Pharmacol       Date:  2010-02       Impact factor: 1.200

9.  Insight in the prediction of chemotherapy-induced nausea.

Authors:  Joseph A Roscoe; Gary R Morrow; Ben Colagiuri; Charles E Heckler; Bryan D Pudlo; Lauren Colman; Karen Hoelzer; Andrew Jacobs
Journal:  Support Care Cancer       Date:  2009-08-23       Impact factor: 3.603

10.  Prevention of delayed nausea: a University of Rochester Cancer Center Community Clinical Oncology Program study of patients receiving chemotherapy.

Authors:  Joseph A Roscoe; Charles E Heckler; Gary R Morrow; Supriya G Mohile; Shaker R Dakhil; James L Wade; J Philip Kuebler
Journal:  J Clin Oncol       Date:  2012-08-20       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.